KarmelSonix is a dynamic young company built on a solid foundation of clinical expertise. A global leader in developing acoustic respiratory monitoring devices, the Company’s ground breaking products are based on acoustic signal acquisition technology and advanced analysis capabilities.
KarmelSonix’s proprietary technology responds to an unmet need for accurate, low cost, easy-to-use devices to identify and quantify the presence of wheezes. The Company is focused on pulmonary acoustics as diagnostic and monitoring tools for managing asthma.
Asthma management requires definite diagnosis, accurate assessment of control, and long term follow up. With KarmelSonix technology it is possible, for the first time, to do so without the need for extensive patient cooperation. Automatic wheeze, cough and breathing detection facilitate quantitative, objective and noninvasive assessment of asthma activity for all ages and around the clock. It optimizes patient care in individuals such as young children, as well as the elderly, and in scenarios where spirometry is not feasible.
KarmelSonix Ltd. (KSL) is the parent company of both KarmelSonix (Israel) Ltd. (KSI), from Haifa, Israel and PulmoSonix Pty. Ltd. (KSA) from Victoria, Australia. KSL fully owns KSI and KSA and is traded on The Australian Stock Exchange (ASX) under the KSX symbol. KSL, KSA and KSI have the same board of directors with Mr. Peter Marks of Melbourne, Australia serving as Chairman, and Dr. Nathan Intrator of Haifa, Israel serving as and Executive Director and CEO of KarmelSonix Ltd. in Israel. The Australian and the Israeli subsidiaries are both focused on pulmonary acoustics as diagnostic and monitoring tools for managing Asthma and other pulmonary disorders
Main business focus/
Listing by sector:
- Medical Devices - Anaesthetic and respiratory devices
KarmelSonix Ltd is a joining of two sector leaders, each with a unique proprietary respiratory acoustic technology:
- KarmelSonix (Israel): Passive technology; an ingenious technique to listen and analyze the lung acoustics generated during the respiratory cycle.
- Pulmosonix (Australia): Active technology that focuses on injecting sounds into the thorax and picking the changed signal at various locations, reaching diagnostic conclusions from the sound propagation data.
The synergy between the technologies and the ability to combine the two approaches, allows Karmelsonix to offer solutions no other market player can tackle. It resolves clinical challenges previously deemed impossible.
|Contact person||PulmoSonix Pty. Ltd.|
|Address||336A Glenhuntly Road|
|Phone||61 3 9532 4283|
|Fax||61 3 9532 4141|